CTXR 外匯新聞
Citius Pharma Announce Positive Topline Results For Pivotal Phase 3 Clinical Trial Of Mino-Lok
Biopharmaceutical company Citius Pharmaceuticals, Inc. (CTXR) announced Tuesday positive topline results of its pivotal Phase 3 clinical trial of Mino-Lok, a novel antibiotic lock solution designed to salvage catheters in patients with central line-associated infections (CLABSI) or catheter-related bloodstream infections (CRBSI).
RTTNews
|
180天前
